When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

On January 6, Caixin News reported (by reporters Lu Afeng and Xiao Lianghua) that after several days of brewing and discussion, the plan for Qingdao Haier Biomedical Co., Ltd. (688139.SH) to acquire Shanghai RAAS Blood Products (002252.SZ) ultimately could not proceed as all parties did not reach a consensus.

This evening, both Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. issued announcements to terminate the major asset restructuring plan, and the stocks of both listed companies will resume trading starting tomorrow.

Previously, the news that Qingdao Haier Biomedical Co., Ltd. would absorb and merge with Shanghai RAAS Blood Products attracted strong attention from both inside and outside the industry, mainly due to the significant difference in the scale of the two companies.

According to the aforementioned announcement, the reason for the termination of the major asset restructuring plan is that 'the transaction counterparty and the major shareholders of the merging parties have had active consultations, repeated discussions, and communications. Due to the complex structure of this transaction, a specific plan recognized by all relevant parties has not yet been formed. After prudently studying the opinions of all parties involved and reaching an agreement through negotiation between the trading parties, to effectively safeguard the interests of the listed company and the broad interests of investors, the trading parties have decided to terminate this transaction.'

When Qingdao Haier Biomedical Co., Ltd. announced the plan to 'absorb and merge' with Shanghai RAAS Blood Products on December 23, 2024, it stated that the starting point of this reorganization is 'to create a first-class comprehensive biotechnological leader, improve the blood ecological Industry Chain layout, leverage synergistic value, and promote the company’s high-quality development.'

Shanghai RAAS Blood Products was officially acquired by Haier Group in mid-2024. On December 29, 2023, Grifols, S.A. (基立福), the original shareholder of Shanghai RAAS, signed a 'Global Strategy and Share Purchase Agreement' with Haier Group, in which Haier Group acquired 1.329 billion shares of Shanghai RAAS held by Grifols, accounting for 20.00% of the company's total equity, with a transfer price of 12.5 billion yuan. At the same time, Grifols entrusted the voting rights corresponding to its remaining 0.437 billion shares to Haier Group, accounting for 6.58% of the company's total equity. On July 30, Shanghai RAAS announced that the change of its controlling shareholder and actual controller had been completed, marking the formal incorporation of Shanghai RAAS into Haier Group's portfolio.

Today, it was announced that the planning for a significant asset restructuring has been terminated, which also means that Qingdao Haier Biomedical Co., Ltd.'s plan to create a "blood products giant" through the merger of two companies has come to a halt.

According to an informed source, before acquiring Shanghai RAAS Blood Products, Haier Group's health brand "INKON Life Technology" had two listed companies, Qingdao Haier Biomedical Co., Ltd. and INKON Life Technology (300143.SZ), whose total revenue for 2023 was less than 4 billion yuan, which is a very low proportion of Haier Group's 260 billion yuan revenue. From the perspective of personnel allocation, Haier Group places great importance on the health sector, and although the merger of Qingdao Haier Biomedical Co., Ltd. and Shanghai RAAS Blood Products has been terminated, Haier Group's objective to expand the health sector remains unchanged.

Both listed companies also announced share repurchase plans today, with Qingdao Haier Biomedical Co., Ltd. and Shanghai RAAS Blood Products repurchasing shares with proprietary funds of 0.1 billion to 0.2 billion yuan and 0.25 billion to 0.5 billion yuan, respectively.

It is reported that Haier Group has been focusing on the layout of the health industry track in recent years and has successfully created the "INKON Life Technology" health ecological brand. The main business of this brand covers multiple fields, including the research and development, production, and application of high-end scientific research equipment, medical instruments, and Medical Services solutions.